CDK4 and breast carcinoma: Indeed, FGFRs contribute to cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance and FGFR1 overexpression reduced the efficacy of CDK4/6i treatment for breast cancer patients enrolled in the MONALEESA-2 study [67].